Table 4.
Multivariate logistic regression analysis showing the effect of inflammatory markers and other variables on the likelihood of POD development.
| Variable | aOR (95% CI) | p Value |
|---|---|---|
| IQR of Inflammatory Markers | ||
| IQR NLR Q2 | 2.26 (1.24–4.14) | 0.008 |
| IQR NLR Q3 | 2.47 (1.3–4.72) | 0.006 |
| IQR NLR Q4 | 2.86 (1.38–5.92) | 0.005 |
| IQR MLR Q2 | 0.87 (0.48–1.56) | 0.636 |
| IQR MLR Q3 | 1.07 (0.6–1.91) | 0.819 |
| IQR MLR Q4 | 1.46 (0.77–2.75) | 0.241 |
| IQR PLR Q2 | 0.5 (0.3–0.84) | 0.008 |
| IQR PLR Q3 | 0.7 (0.42–1.16) | 0.168 |
| IQR PLR Q4 | 0.48 (0.27–0.85) | 0.011 |
| IQR CAR Q2 | 0.92 (0.52–1.63) | 0.782 |
| IQR CAR Q3 | 1.53 (0.9–2.59) | 0.116 |
| IQR CAR Q4 | 1.6 (0.94–2.72) | 0.085 |
| Other variables | ||
| Age | 1.05 (1.03–1.07) | <0.001 |
| Male | 1.8 (1.22–2.65) | 0.003 |
| Obesity (BMI > 29.9) | 0.72 (0.33–1.53) | 0.39 |
| ASA physical status > 2 | 2.07 (1.37–3.13) | <0.001 |
| Emergency surgery | 0.92 (0.38–2.23) | 0.852 |
| HTN | 0.77 (0.53–1.12) | 0.174 |
| DM | 0.95 (0.64–1.4) | 0.779 |
| Heart disease | 0.71 (0.44–1.16) | 0.171 |
| Stroke | 1.04 (0.58–1.88) | 0.885 |
| Cancer | 0.52 (0.28–0.99) | 0.047 |
| Dyslipidemia | 0.66 (0.4–1.11) | 0.12 |
| Parkinson’s disease | 4.46 (1.76–11.29) | 0.002 |
| Dementia | 3.8 (1.4–10.31) | 0.009 |
| Depression | 2.64 (1.14–6.16) | 0.024 |
| Kidney disease | 0.78 (0.37–1.61) | 0.496 |
| Liver disease | 0.48 (0.17–1.4) | 0.179 |
| Insomnia | 0.9 (0.07–12.27) | 0.937 |
| Sleep disorder | 1.64 (0.11–23.51) | 0.717 |
| Alcohol | 0.66 (0.4–1.08) | 0.097 |
| Smoking | 1.1 (0.66–1.85) | 0.714 |
| Calcium channel blockers | 0.85 (0.6–1.21) | 0.37 |
| Diuretics | 0.76 (0.43–1.32) | 0.328 |
| Beta blockers | 0.79 (0.4–1.55) | 0.486 |
| ACE inhibitors | 0.95 (0.08–11.84) | 0.97 |
| Angiotensin receptor blockers | 1.13 (0.54–2.38) | 0.741 |
| Other antihypertensives | 0.25 (0.03–2.31) | 0.222 |
| Miscellaneous CV drugs | 1.51 (0.75–3.03) | 0.247 |
| Antidepressants | 0.64 (0.21–1.93) | 0.424 |
| Hypnotic sedatives | 1.07 (0.71–1.61) | 0.749 |
| Antipsychotics | 3.52 (2.08–5.97) | <0.001 |
| Opioids | 0.69 (0.08–6.09) | 0.734 |
| Corticosteroids | 1.16 (0.8–1.68) | 0.43 |
| Antihistamine antiallergics | 1.41 (0.95–2.11) | 0.089 |
| H2 receptor antagonist | 1.08 (0.71–1.62) | 0.729 |
| Operation time | 1.11 (0.97–1.26) | 0.118 |
| Surgical range | 1.13 (0.96–1.32) | 0.146 |
| Fluid balance (input–output) | 0.91 (0.75–1.12) | 0.383 |
| Postop. ICU care | 3.83 (2.59–5.65) | <0.001 |
| Patient-controlled analgesia | 1.13 (0.45–2.81) | 0.796 |
IQR, interquartile range; aOR, adjusted odds ratio; CI, confidence interval; NLR, neutrophil-to-lymphocyte ratio; MLR, monocyte-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; CAR, CRP-to-albumin ratio.